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ABSTRACT Although more than three decades have passed since the first use 
of minoxidil in androgenetic alopecia (AgA), its mechanisms of action have 
still not been comprehensively understood. 5α-reductase (5α-r) has an ac-
tive role as the predominant enzyme in both AgA and female pattern hair loss 
(fPHl), which are also the main therapeutic indications of topical minoxidil. 
But there is insufficient literature data regarding the interaction of minoxidil 
and the enzyme 5α-r. Herein, we studied the in vitro expression levels of 5α-r 
type 2 (5α-r2) in a minoxidil-treated human keratinocyte cell line (HaCat) in 
order to elucidate the relation of these two parameters. Cell proliferation assay 
was performed by a Xtt reagent (a yellow tetrazolium salt). After determina-
tion of non-cytotoxic concentration, HaCat cells were treated with minoxidil. 
ribonucleic acid (rnA) isolations were carried out from both non-treated and 
treated cell groups using a tri reagent (an rnA, DnA, and protein isolation 
reagent). gene expressions of 5α-r2 as study material and glyceraldehyde-3-
phosphate dehydrogenase (gAPDH) as the control were determined by real 
time-quantitative polymerase chain reaction (rt-qPCr) analysis. results were 
represented as 5α-r2 / gAPDH fold change. Minoxidil treatment resulted in a 
0.22 fold change for 5α-r2 (p < 0.0001). this antiandrogenic effect of minoxidil, 
shown by significant downregulation of 5α-r2 gene expression in HaCat cells, 
may be one of its mechanisms of action in alopecia.
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INTRODUCTION
Oral minoxidil has been used to treat hypertension 
since 1960s. Hypertrichosis as a consequence of min-
oxidil treatment was observed shortly thereafter, and 
these observations led to the development of topical 
minoxidil as a treatment for hair loss. Although it is 
being used for the treatment of male androgenetic 
alopecia (AgA) and female pattern hair loss (fPHl) for 
approximately three decades, but our understanding 
of its mechanisms of action on the hair follicle is still 
very limited (1,2). Due to the blood pressure lower-
ing effect of oral minoxidil through relaxing the vas-
cular smooth muscle by the action of its sulphated 
metabolite, as an opener of sarcolemmal adenosine 
triphosphate sensitive potassium channels (KAtP ), it is 
postulated that its stimulatory effect on hair growth 
is also related with the opening of potassium chan-
nels (1,3,4). Cutaneous blood flow was observed to 
increase 10-15 minutes after the application of topi-
cal minoxidil (5). A number of in vitro effects of min-
oxidil have been described in monocultures of vari-
ous skin and hair follicle cell types including stimu-
lation of cell proliferation, slowing the senescence of 
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keratinocytes, inhibition of collagen synthesis, stimu-
lation of vascular endothelial growth factor (Vegf), 
and prostaglandin synthesis (1,6-8). some or all of 
these effects may be relevant to hair growth, but the 
application of results obtained in cell culture studies 
to the complex biology of the hair follicle is uncertain 
(1). 
Although polygenic heredity is assumed to be 
the primary cause, androgens play an important 
role in both AgA and fPHl, seemingly independent 
of genetic predisposition (9). Androgen-dependent 
processes are predominantly due to the binding of 
dihydrotestoerone (DHt) to the androgen receptor 
(Ar). the predisposed scalp exhibits high levels of 
DHt and increased expression of Ar. DHt-related cell 
functions depend on the availability of weak andro-
gens, i.e. their conversion to more potent androgens 
via the action of 5α-reductase (5α-r), low enzymatic 
activity of androgen inactivating enzymes, and func-
tionally active Ars present in high numbers (10). 
Although 5α-r has an active role as the predomi-
nant enzyme in both AgA and fPHl, which are also 
the main therapeutic indications of topical minoxidil, 
there is insufficient literature data about the interac-
tion of the two. Herein, we studied in vitro expression 
levels of 5α-r type 2 (5α-r2) in a minoxidil-treated hu-
man keratinocyte cell line (HaCat) in order to eluci-
date the relation of these two parameters.
PATIENTS AND METHODS
Cell Culture
HaCat was cultured in Dulbecco’s Modified eagle’s 
medium with high glucose, supplemented with 10% 
heat-inactivated fetal bovine serum and 100 U/ml 
gentamicin. the cells were maintained at 37°C in a 
humidified atmosphere at 5% CO2 in a newbruns-
wick incubator. All supplements and media were pur-
chased from sigma Aldrich.
Preparation of Minoxidil Solution
We dissolved 522.5 mg minoxidil in 25 ml distilled 
water – 25 ml ethanol mixture to get a 5 mM minoxi-
dil solution. this solution was used as a 100% sample, 
and other concentrations (10.0%, 5.0%, 3.0%, 1.0%, 
and 0.2%) of the solution were prepared by dilution 
with distilled water.
Cell Proliferation Assay
HaCat cells were seeded into 96-well plates (1×104 
cells/well) and were subjected to different concentra-
tions of minoxidil solution to assess the cell prolifera-
tion. An Xtt reagent (a yellow tetrazolium salt), was 
added to the plates after a 72-hour incubation period 
according to the manufacturer’s (roche) instructions. 
Cells were then incubated at 37oC for 4 hours in or-
der to reduce the Xtt reagent to an orange formazan 
compound. the optical density of the soluble forma-
zan compound was measured at 495 nm by a micro-
plate reader (Bio-rad).
Ribonucleic Acid (RNA) Isolation and Re-
verse Transcription
total rnA was extracted from cells treated with 
minoxidil solution and from untreated cells using a tri 
reagent (an rnA, DnA, and protein isolation reagent), 
according to the manufacturer’s (sigma Aldrich) in-
structions. the concentration and purity of isolated 
rnA samples were determined by measuring opti-
cal densities at 260 nm and 280 nm using Biospec-
nano. the transcriptor first strand cDnA synthesis Kit 
(roche) was used for reverse transcription. Comple-
mentary deoxyribonucleic acid (cDnA) synthesis was 
performed with 500 ng total rnA; 2 µM of each final 
concentration of gene-specific primers of 5α-r2 as 
study material and glyceraldehyde-3-phosphate de-
hydrogenase (gAPDH) as the control (integrated DnA 
technologies); 10 U of transcriptor reverse transcrip-
tase; 20 U of Protector rnase inhibitor; 1 mM each 
of dntP mix and transcriptor reverse transcription 
Buffer (5X) according to the manufacturer’s (roche) 
instructions. Primer sequences (5 ‘ – 3’) are presented 
in table 1.
Real-Time Quantitative Polymerase Chain 
Reaction (RT-qPCR)
rt-qPCr was carried out in light Cycler 96 (roche). 
Amplification of products was detected via interca-
lation of the sYBr green fluorescent dye (fast start 
DnA green Master Kit, roche). Briefly, total volume of 
reaction mix was 20 µl; containing 10 µl sYBr green 
Master Mix (×2), 0.5 µM of reverse and forward prim-
ers, 2.5 ng cDnA, and the appropriate amount of nu-
clease free water. All samples were run as triplicates in 
Table 1. Primers (5’ – 3’) of the genes studied
Primers Forward primer Reverse primer
5α-r2 CgCtCtACCAgtACgCCAg AAttAAgCACCgAtgCCCgt
gAPDH AtgggtgtgAACCAtgAgAA gtgCtAAgCAgttggtggtg
5α-r2: 5α-reductase; gAPDH: glyceraldehyde-3-phosphate dehydrogenase used as control
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each run, including a non-template control and four 
standards (1:1, 1:10, 1:100, 1:1000). the rt-qPCr pa-
rameters were determined separately for each target 
according to melting and annealing temperatures of 
primers. each parameter included a pre-incubation 
step for 10 min at 95°C and followed by 45 cycles of 
three amplification and melting steps. Melting curve 
analysis was performed to verify specificity. for quan-
titation of rt-qPCr results, the ΔΔCt method was 
used (2-ΔΔCt).
Statistical Analysis
All data are representative of three repetitions 
(n=3) and expressed as mean ± standard error of the 
means (seM). statistical evaluation was performed by 
an unpaired t-test, using graph Pad Prism 5 software 
(UsA); results with a P value less than 0.05 were ac-
cepted as significant.
RESULTS
Cytotoxicity Analysis (Cell Proliferation 
Assay)
Based on cell proliferation ratios of treated cells 
with respect to the control cells, cytotoxicity levels 
of the minoxidil solution were determined. Higher 
concentrations were found to be cytotoxic for HaCat 
cells. for the subsequent analysis, the possible high-
est concentration was determined as 1%, and HaCat 
cells were incubated with 1% concentration of min-
oxidil solution before total rnA isolation (figure 1).
Gene Expression Analysis (RT-qPCR)
results were represented as target / gAPDH fold 
Change. results of gene expression analysis via rt-
qPCr showed that minoxidil solution caused sta-
tistically significant downregulation of 5α-r2 gene 
expressions, compared with untreated control cells. 
Minoxidil treatment resulted in 0.22 fold changes 
(P<0.0001) for 5α-r2 (figure 2).
DISCUSSION
the pilosebaceous unit is the site of numerous cell 
interactions, and although the histology and struc-
ture of the follicle is well-known today, the molecular 
events controlling the hair cycle remain obscure. the 
development of in vitro and in vivo models, however, 
have provided some insights on the role of growth 
factors such as insulin like growth factor-1 (igf-1), 
transforming growth factor-α (tgf-α), and Vegf, as 
well as androgens such as DHt and cytokines such as 
interleukin-1 (il-1) (7,11).
Although the basic etiopathogenesis is not thor-
oughly understood, besides the aspect of genetic 
predisposition, the role of androgens in AgA is well 
established (2,10,12,13). the concentrations of DHt, 
5α-r, and Ars are increased in a balding scalp. the 
higher the concentration of androgens and Ars, the 
greater the effect on the expression of genes which 
control follicular cycling (14). the finding indicate 
Xq12, the X chromosome region which encodes the 
Ar, may represent a common genetic factor under-
lying both AgA and fPHl (15-18). Although the X 
chromosomal location of the Ar gene indicates that 
the maternal line is the major inheritance of AgA in 
men, family studies showing resemblance of hair loss 
between fathers and sons suggest that some autoso-
mal genes might also contribute to the phenotype 
(2,16,19). in a study on the identification of new sus-
ceptibility genes, strong evidence was found for an 
alopecia susceptibility locus on chromosome 3q26 
(19). in another study, significant association was 
found with AgA on chromosome 20p11, suggesting 
that the 20p11 locus has a role in a yet-to-be-identi-
fied androgen independent pathway (20). it was later 
reported that although this locus is responsible from 
AgA, it has no association with fPHl (17,18).
On the other hand, contradicting results have 
been reported on the interaction of minoxidil and 
Figure 1. Cytotoxicity analysis result of minoxidil solution. 
the dashed bar represents the concentration chosen for 
incubation. Figure 2. gene expression level of 5α-reductase type 2 af-
ter minoxidil treatment, compared with untreated control 
cells
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its androgen-dependent mechanisms of action: in 
a study on the effect of minoxidil on testosterone 
metabolism through cultured dermal papilla cells of 
balding or non-balding scalp and dermal fibroblasts, 
5α-r activity was slightly increased in dermal papilla 
cells of a balding scalp, while there was no increase in 
other groups of cells. in the same study, the increase 
of 17β-hydroxysteroid dehydrogenase activity was 
much higher with minoxidil in dermal papilla cells of 
a balding scalp (21). in another study, minoxidil was 
found to be a weak inhibitor of human hair follicle 5α-
r (22). Although one study found no antiandrogenic 
potential of minoxidil on androgen-dependent cuta-
neous structures in an animal model (23), it was con-
tradicted by another group because female animals 
were used in the trial, and testosterone which can 
be converted to estradiol in hair follicles, rather than 
DHt, was chosen. the later study analyzing the anti-
androgenic potential of minoxidil claimed that min-
oxidil suppresses Ar-related functions by decreasing 
Ar transcriptional activity and reducing the expres-
sion of Ar targets at the protein level (24). 
the significant suppression of 5α-r2 in HaCat cells 
by minoxidil in our study, although not at the recep-
tor level, supports the thesis of minoxidil’s antiandro-
genic mechanism of action. this thesis, together with 
the literature data on the X chromosome-linked Ar 
pathway and the autosomal chromosome-linked an-
drogen independent pathway in the etiopathogen-
esis of alopecia, it may provide a better explanation 
of why some patients do not respond well to minoxi-
dil therapy. Although further studies are needed, this 
thesis may also allow the exclusion of poor respond-
ers to minoxidil therapy and avoid waste of time in 
clinical practice by identifying probable androgen-in-
dependent alopecia patients to some extent. 
CONCLUSION
the antiandrogenic effect of minoxidil, demon-
strated by significant downregulation of 5α-r2 gene 
expression in HaCat cells in our study, may be one 
of its mechanisms of action in AgA and fPHl, which 
is not being emphasized well in the dermatology 
literature. 
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